NFL and CXCL13 reveal disease activity in clinically and neuro-radiologically stable MS

被引：0
|
作者：
Novakova, L. [1 ]
Axelsson, M. [1 ]
Malmestrom, C. [1 ]
Svenningsson, A. [2 ]
Zetterberg, H. [3 ]
Blennow, K. [3 ]
Lycke, J. [1 ]
机构：
[1] Gothenburg Univ, Sahlgrenska Acad, Clin Neurocience, Inst Neurosci & Physiol, Gothenburg, Sweden
[2] Karolinska Inst, Stockholm, Sweden
[3] Gothenburg Univ, Inst Neurosci & Physiol, Sahlgrenska Acad, Psychiat & Neurochem, Gothenburg, Sweden
来源：
MULTIPLE SCLEROSIS JOURNAL | 2017年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EP1605
引用
收藏
页码：841 / 841
页数：1
相关论文
共 42 条
  • [21] B-Cell-Attracting Chemokine CXCL13 As a Marker of Disease Activity in Systemic Lupus Erythematosus (SLE)
    Omran, Eman Ahmed Hamed
    El-Hakeim, Eman H.
    Galal, Marwa A. A.
    Nasr, Nada M. M.
    Mosaad, Eman
    AKTUELLE RHEUMATOLOGIE, 2019, 44 (02) : 115 - 120
  • [22] SERUM CXCL13 LEVELS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ITS CORRELATION TO DISEASE ACTIVITY AND LUPUS NEPHRITIS
    Abdalla, A. M.
    Baraka, E. A. E.
    El-Bhissy, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1224 - 1224
  • [23] Assessment of synovitis in early rheumatoid arthritis by CXCL13 serum levels and power Doppler ultrasonography: Correlation with disease activity
    Ahmed, Sahar Fathi
    Badr, Takwa
    Hosny, Sherin Mohamed
    Hamayed, Hazem Fawzy Aboul
    EGYPTIAN RHEUMATOLOGIST, 2013, 35 (01): : 21 - 27
  • [24] Serum CXCL13 As a Biomarker of Disease Activity and Severity in Rheumatoid Arthritis: Comparison with Acute Phase Reactants and the Autoantibody Profile
    Manzo, Antonio
    Bugatti, Serena
    Vitolo, Barbara
    Benaglio, Francesca
    Binda, Elisa
    Scarabelli, Martina
    Caporali, Roberto
    Montecurcco, Carlomaurizio
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S439 - S440
  • [25] Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab
    Katie Tuckwell
    Cem Gabay
    Thierry Sornasse
    Ruediger Paul Laubender
    Jianmei Wang
    Michael J. Townsend
    Advances in Rheumatology, 59
  • [26] Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab
    Tuckwell, Katie
    Gabay, Cem
    Sornasse, Thierry
    Laubender, Ruediger Paul
    Wang, Jianmei
    Townsend, Michael J.
    ADVANCES IN RHEUMATOLOGY, 2019, 59 (01) : 54
  • [27] CXCL13 and BOB1 expression in initial biopsies of mycosis fungoides with stable early stage and later tumor stage disease
    Wehkamp, U.
    Oschlies, I.
    Kohler, C.
    Weichenthal, M.
    Klapper, W.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 (03) : E92 - E92
  • [28] B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE)
    Schiffer, Lena
    Kuempers, Philipp
    Davalos-Misslitz, Ana. M.
    Haubitz, Marion
    Haller, Hermann
    Anders, Hans-Joachim
    Witte, Torsten
    Schiffer, Mario
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (12) : 3708 - 3712
  • [29] SERUM CXCL13 AS A BIOMARKER OF DISEASE ACTIVITY AND SEVERITY IN IN RHEUMATOID ARTHRITIS. COMPARISON WITH ACUTE PHASE REACTANTS AND THE AUTOANTIBODY PROFILE
    Bugatti, S.
    Manzo, A.
    Vitolo, B.
    Benaglio, F.
    Binda, E.
    Scarabelli, M.
    Caporali, R.
    Montecucco, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 371 - 371
  • [30] Elevated CXCL13 in primary Sjogren's syndrome and its correlation with disease activity: a systematic review and meta-analysis
    Zhu, Tong
    Pan, Zijian
    Zhang, Nannan
    CLINICAL RHEUMATOLOGY, 2022, 41 (09) : 2791 - 2802
12345